Zoetis to Buy Fish Vaccine Maker for $765 Million
November 02 2015 - 8:10PM
Dow Jones News
Zoetis Inc. agreed to buy Pharmaq, a major maker of vaccines for
farmed fish, for $765 million.
The acquisition would allow veterinary drug maker Zoetis to
capitalize on increasing demand for farmed fish. Farmed fish
account for about half of total fish consumption, up from 15% in
1990, the company said in a news release.
Pharmaq, which is majority owned by global investment firm
Permira, generated roughly $80 million in revenue in 2014. The
Oslo, Norway, company has about 200 employees. Pharmaq's late-stage
development pipeline includes new vaccines and next-generation
parasiticides expected to enter the Norwegian, Chilean and U.K.
markets in the near term.
Zoetis, which was spun off by drug company Pfizer Inc. in 2013,
is the world's leading seller of vaccines and medicines for
livestock and household pets by sales.
After the deal closes, expected on or about Nov. 10, Pharmaq is
expected to run largely as a stand-alone operation within Zoetis.
The transaction is expected to add to Zoetis's earnings in
2017.
During August, Zoetis reported that it swung to a second-quarter
loss on costs related to its restructuring plans, though revenue
and adjusted profit topped expectations as sales of its pet and
livestock medicines grew.
The Florham Park, N.J., company is expected to provide more
details about the planned acquisition during its third-quarter
earnings conference call on Tuesday.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 02, 2015 19:55 ET (00:55 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024